{'fraction_non_alphanumeric': 0.020891364902506964, 'fraction_numerical': 0.02924791086350975, 'mean_word_length': 5.145299145299146, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Medical management of renal scleroderma.

Progressive systemic sclerosis (diffuse scleroderma) is a disease of unknown cause characterized by widespread alterations of connective tissue, vascular lesions in many organs and by a variety of vasomotor abnormalities among which Raynaud's phenomenon is the most common. Renal involvement in progressive systemic sclerosis (mentioned by Osier in 1892 and described in detail by Moore and Sheehan in 1952) has been shown in several more recent studies to be the major factor that adversely affects prognosis in the disease.1 , 2 In a study of 210 patients seen at Columbia–Presbyterian Medical Center from 1952 to 1972 proteinuria, hypertension or azotemia occurred in . . .